Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Free Cash Flow (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Free Cash Flow for 6 consecutive years, with -$17.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 21.54% to -$17.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$67.9 million through Dec 2025, up 62.27% year-over-year, with the annual reading at -$67.9 million for FY2025, 62.27% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$17.2 million at Lexicon Pharmaceuticals, up from -$23.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was $17.0 million in Q2 2025, with the low at -$55.1 million in Q1 2024.
  • Average Free Cash Flow over 3 years is -$34.2 million, with a median of -$40.0 million recorded in 2023.
  • The sharpest move saw Free Cash Flow crashed 73.03% in 2024, then skyrocketed 134.83% in 2025.
  • Over 3 years, Free Cash Flow stood at -$50.5 million in 2023, then skyrocketed by 56.55% to -$22.0 million in 2024, then grew by 21.54% to -$17.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$17.2 million, -$23.8 million, and $17.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.